A postpartum care model combining health coaching with self-measured blood pressure (BP) monitoring significantly improved both health care engagement and blood pressure control by 12 months post partum,… read more.
Shield Therapeutics announced the publication of the positive efficacy, tolerability and palatability results from the ferric maltol pediatric FORTIS clinical trial, comparing the safety and efficacy of ferric… read more.
For people with lymphoma, getting the right diagnosis can be a race against time. Symptoms such as swollen lymph nodes, fever, weight loss and fatigue can be signs… read more.
More people with disabilities were actively looking for work in July compared to June, while the number of people without disabilities seeking employment declined over the same period…. read more.
Merck, known as MSD outside of the United States and Canada, announced the Phase 3 KEYNOTE‑C93 trial evaluating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, met its primary endpoint of… read more.
The new drug is a starting point for therapies that treat OA at its source. Osteoarthritis (OA) is a chronic, painful joint disease and a leading cause of… read more.
Premarket evidence and regulatory characteristics offered little predictive value, researchers report in JAMA Health Forum More than one-third of high-risk therapeutic medical devices authorised for use in the… read more.
JCR Pharmaceuticals announced its development plan in Japan for givinostat, a treatment for Duchenne muscular dystrophy (DMD), following consultation with the Pharmaceuticals and Medical Devices Agency (PMDA). Based… read more.
Having high blood pressure is associated with greater intentions to follow doctors’ recommendations to take medication than people without high blood pressure but lesser intentions to make recommended… read more.
The first evidence that night work and chronic insomnia may increase the risk of developing long COVID comes from a new study led by ISGlobal, a centre supported by “la Caixa” Foundation,… read more.
Merck BioPharma K.K., the Japanese subsidiary of Merck KGaA, began participant registration for a Phase III trial evaluating the efficacy and safety of fixed-dose combinations of follitropin alfa… read more.
The MHRA has approved Romvimza (vimseltinib ) to treat adult patients with tenosynovial giant cell tumour (TGCT) when it impacts movement or where surgery is not an option. TGCT (Giant cell… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
